1 / 21

Functional Diffusion Maps (fDMs) for Brain Tumor Treatment Response Monitoring

Functional Diffusion Maps (fDMs) for Brain Tumor Treatment Response Monitoring. Benjamin M. Ellingson, Ph.D. Assistant Professor of Radiology Dept. of Radiological Sciences David Geffen School of Medicine at UCLA.

keran
Download Presentation

Functional Diffusion Maps (fDMs) for Brain Tumor Treatment Response Monitoring

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Functional Diffusion Maps (fDMs) for Brain Tumor Treatment Response Monitoring Benjamin M. Ellingson, Ph.D. Assistant Professor of Radiology Dept. of Radiological Sciences David Geffen School of Medicine at UCLA B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  2. Diffusion MRI is sensitive to tumor cell density • Clinical ADC and cell density are negatively correlated • (Sugahara, 1999; Lyng, 2000; Chenevert, 2000; Gaurain, 2001; Nonomura, 2001; Guo, 2002; Chen, 2005; Hayashida, 2006; Manenti, 2008; Kinoshita, 2008; Ellingson, 2010) • ADC (or mean diffusion) = cell density (“hypercellularity”) • ADC =  cell density (“hypocellularity”) Edema Necrotic Core Viable Tumor (Dark) ADC Map B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  3. ADC correlates with brain tumor cell density • Untreated glioma patients (WHO II-IV) underwent diagnostic stereotactic biopsy • (n = 17) biopsy sites were spatially matched to the pre-operative ADC map R2 = 0.7933; P < 0.001 ADC Sensitivity = 1.01 x 10-7 [mm2/s]/[nuclei/mm2] B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011 From: Ellingson BM et al., J Magn Reson Imaging, 2010

  4. The Functional Diffusion Map (fDM)(Moffat, 2005; 2006; Hamstra, 2005; 2008; Ellingson, 2009; 2010; 2011) From: Ellingson, JMRI, 2009, In Press B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  5. The Functional Diffusion Map (fDM)(Moffat, 2005; 2006; Hamstra, 2005; 2008; Ellingson, 2009; 2010; 2011) From: Ellingson, JMRI, 2009, In Press B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  6. Early Detection of Brain Tumor Growth T1+C Contrast-Enhancement (white) FLAIR fDMs B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  7. fDMs in Brain Tumor Progression 3 mo. 6 mo. 9 mo. (Onset of symptoms) T1+C FLAIR fDM B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  8. fDMs in Progressive Disease (PD) Hypercellularity Hypercellularity Hypercellularity From: Ellingson, ISMRM, 2009; SNO, 2009 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  9. fDM Results in Stable/Responding Disease (SD/RD) Hypocellularity Hypocellularity Hypocellularity From: Ellingson, ISMRM, 2009; SNO, 2009 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  10. fDMs May Reflect Molecular/Genetic Phenotypes MGMT(+) MGMT(-) MGMT(+) MGMT(-) MGMT(+) MGMT(-) From: Ellingson, ISMRM, 2009; SNO, 2009 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  11. fDMs May Reflect Molecular/Genetic Phenotypes From: Ellingson, ISMRM, 2009; SNO, 2009 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  12. Clinical fDM Sensitivity/Specificity WHO Grade (n = 50 Total Patients) Spearman Corr. Coeff. R = 0.4350, P = 0.0016 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011 From: Ellingson BM et al., ISMRM, 2010

  13. Clinical fDM Sensitivity/Specificity Neurological Status (n = 50 Total Patients) Pearson Corr. Coeff. R2 = 0.8586, P < 0.0001 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011 From: Ellingson BM et al., ISMRM, 2010

  14. fDMs Before/After Radiotherapy N = 94 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  15. fDMs Before/After Bevacizumab N = 77 B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  16. Graded fDMs B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  17. Graded fDMs:Tumor Invasion Beyond FLAIR B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  18. Graded fDMs for StealthStation™ Biopsy Localization B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  19. Graded fDMs in Differential DiagnosisTumor vs. Demyelination Hypercellular Hypocellular Macrophages & Inflammatory Cells Demyelination Biopsy Diagnosis = Demyelination (Multiple Sclerosis) B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  20. Graded fDMs – Radiation Necrosis T1+C FLAIR Hypercellular Graded fDM Hypocellular B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

  21. Stereotactic fDMs Using a Neuroanatomical Atlas Overlaid On T1 Atlas Anatomy Label Map B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

More Related